Solid Biosciences (SLDB) CFO Awarded 187,500 Equity Units on 08/14/2025

Rhea-AI Filing Summary

Kevin Tan, CFO & Treasurer of Solid Biosciences Inc. (SLDB), received equity awards on August 14, 2025. The Form 4 shows a grant of 125,000 employee stock options with an exercise price of $6.17 and 62,500 restricted stock units (RSUs), each RSU representing a right to one share. The awards vest over four years: 50% of the original shares vest on the second anniversary of the grant and 25% vest annually thereafter until the fourth anniversary. Following the reported transaction, Mr. Tan beneficially owns 125,000 shares from the option and 62,500 shares from RSUs as direct ownership. The Form 4 was signed by Kimberly Cornwell as attorney-in-fact on 08/18/2025.

Positive

• Total awards of 187,500 underlying shares provide clear alignment between the CFO's compensation and shareholder value creation.
• Time-based vesting (50% at year two, then 25% annually) supports executive retention over a multi-year horizon.

Negative

• Potential dilution of 187,500 shares to existing shareholders from the option and RSU awards (aggregate amount disclosed on this Form 4).
• Form 4 lacks company-wide share count or percentage ownership context, so the materiality of these awards to overall capitalization cannot be assessed from this filing alone.

Insights

Financial Analyst

TL;DR: Executive equity grants total 187,500 underlying shares, aligning pay with shareholder value but creating modest dilution.

The grant of 125,000 options at a $6.17 exercise price plus 62,500 RSUs represents a meaningful equity award for a senior executive and is structured with multi-year vesting to incentivize retention and performance. The option exercise price is explicit at $6.17 and RSUs convert one-for-one to common stock. These awards are standard for executive compensation and likely reflect ongoing incentive practices rather than extraordinary dilution. Investors should note the total number of underlying shares granted (187,500) when assessing share count changes, although the Form 4 does not disclose company-wide share counts or percentage dilution.

Corporate Governance Expert

TL;DR: Award structure uses time-based vesting with back-loaded vesting (50% at year two), consistent with retention-focused design.

The awards vest over four years with a 50% cliff at the second anniversary and subsequent 25% annual vesting, which prioritizes medium-term retention. The RSUs provide direct equity exposure upon vesting, while the options provide upside contingent on stock performance above $6.17. The filing is properly completed and signed by an attorney-in-fact. The disclosure does not include grant approvals, comparator peer practices, or impact on executive compensation limits, so evaluation of governance quality is limited to the award terms disclosed on this Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tan Kevin

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MA 02129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$6.17	08/14/2025		A		125,000		(1)	08/14/2035	Common Stock	125,000	$0.00	125,000	D
Restricted Stock Units	(2)	08/14/2025		A		62,500		(1)	(1)	Common Stock	62,500	$0.00	62,500	D

Explanation of Responses:

1. The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary.

2. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

	/s/ Kimberly Cornwell as attorney-in-fact for Kevin Tan	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Kevin Tan (SLDB) receive on the August 14, 2025 grant?

He received 125,000 employee stock options with an exercise price of $6.17 and 62,500 restricted stock units (RSUs), granted on 08/14/2025.

How do the awards to Kevin Tan vest?

Vesting is over four years with 50% of the original number of shares vesting on the second anniversary of the grant date and 25% annually thereafter until the fourth anniversary.

How many shares do the awards represent in total?

The awards represent an aggregate of 187,500 underlying shares (125,000 from options plus 62,500 from RSUs) as disclosed on the Form 4.

Who filed and signed the Form 4 for Kevin Tan and when?

The Form 4 was signed by Kimberly Cornwell as attorney-in-fact for Kevin Tan on 08/18/2025.

What is the exercise price and expiration relevant to the options?

The employee stock option exercise price is $6.17; the Form 4 shows the option grant and lists related dates but does not provide company-wide capitalization details.